Access to MDR-TB treatment improved with the availability of delamanid
Positive news in treatment options for Multi-Drug Resistant tuberculosis (MDR-TB).
In the lead up to World TB Day on March 24th, there is positive news in treatment options for Multi-Drug Resistant tuberculosis (MDR-TB). Delamanid, an essential MDR-TB medicine, is now available to TB patients through the Stop TB Partnership’s Global Drug Facility (GDF). As exclusive procurement agent for GDF, IDA Foundation was able to contribute to this development in concluding a Long-Term Agreement (LTA) with Otsuka, manufacturer of delamanid, to ensure continued access to this essential medicine. Delamanid is one of two new life-saving medicines recently approved to combat multidrug-resistant (MDR) tuberculosis, the other being bedaquiline. These two therapies have the potential to dramatically improve MDR-TB treatment outcomes and reduce TB mortality worldwide.
Tuberculosis is a disease that continues to kill around 1.5 million people worldwide per year, with new cases of drug-resistant forms affecting nearly half a million people annually. According to World Health Organization, barely a quarter of people thought to have MDR-TB had access to treatment in 2014, with only about half of those successfully completing treatment. Coordinated programmes to help access and continue these new therapies are essential if the world is to meet the targets in the Global Plan to End TB 2016 -2020 and further World Health Organization’s (WHO) ambitious goal to end TB as a global health threat by 2035.
Considering those statistics, and that bedaquiline and delamanid are the first new anti-TB medicines to be developed in over fifty years, the addition of these new therapies offers hope for TB patients suffering from resistant forms of the disease.
For more information on the Global Drug Facility / Stop TB Partnership, visit www.stoptb.org